Cassava Sciences Inc vs T Rowe Price Group Inc — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while T Rowe Price Group Inc trades at $116.99 (market cap $24.26B). The key difference: T Rowe Price Group Inc is far larger — about 508.1× Cassava Sciences Inc's market cap, and T Rowe Price Group Inc pays a 4.57% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | TROW | |
|---|---|---|
Market Cap | $47.75M | $24.26B |
Sector | Health | Financials |
52-Week High | $4.64 | $121.68 |
52-Week Low | $0.87 | $86.19 |
Enterprise Value | -$34.93M | $21.46B |
Dividend Yield | — | 4.57% |
Trailing returns across standard periods
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →